Wallace R A, Wallace L, Harrold M, Miller D, Uretsky N J
Division of Pharmacology, College of Pharmacy, Ohio State University, Columbus 43210.
Biochem Pharmacol. 1989 Jun 15;38(12):2019-25. doi: 10.1016/0006-2952(89)90502-9.
Although a structural feature common to all dopaminergic agonists and antagonists is a side-chain basic amino group, it is unclear whether this moiety binds to the D-1 dopamine (DA) receptor in the charged or uncharged form. To obtain information on this point, we synthesized permanently charged dimethylsulfonium and quaternary ammonium analogs of chlorpromazine and DA and determined whether these compounds can bind to the D-1 receptor by measuring their abilities to inhibit the binding of SCH 23390, a D-1 receptor antagonist. Chlorpromazine and the dimethylsulfonium and trimethylammonium analogs of chlorpromazine were found to inhibit the binding of [3H]SCH 22390, which was maximally inhibited to the same extent by all three compounds. In addition, inhibition curves for the compounds fit a one-site binding model, indicating binding to a single class of sites. However, while the permanently charged chlorpromazine analogs were able to inhibit [3H]SCH-23390 binding, they were considerably less potent than chlorpromazine. DA and dimethyl DA were also able to inhibit [3H]SCH 23390 binding. However, the permanently charged dimethylsulfonium and trimethylammonium analogs of DA were ineffective in inhibiting [3H]SCH 23390 binding. In addition, the permanently uncharged methylsulfide analog did not inhibit binding. These studies show that permanently charged analogs of chlorpromazine can bind to the striatal D-1 receptor, which is consistent with an anionic recognition site on the D-1 receptor that interacts with antagonists in the cationic form. In addition, it appears that a nitrogen atom is not required for binding to the D-1 receptor, since the sulfonium analog of chlorpromazine bound to the receptor to the same extent as chlorpromazine. However, since the permanently charged or uncharged analogs of DA did not bind to the D-1 receptor, it is still unclear as to whether the charged form of a dopaminergic agonist can bind. The lower potency or ineffectiveness of the permanently charged analogs compared to the parent amines (chlorpromazine, DA, dimethyl DA) in binding to the D-1 receptor may reflect the inability of the permanently charged analogs to undergo hydrogen binding with the anionic site of the receptor.
尽管所有多巴胺能激动剂和拮抗剂共有的一个结构特征是侧链碱性氨基,但尚不清楚该部分是以带电形式还是不带电形式与D-1多巴胺(DA)受体结合。为了获得关于这一点的信息,我们合成了氯丙嗪和DA的永久带电的二甲锍和季铵类似物,并通过测量它们抑制D-1受体拮抗剂SCH 23390结合的能力来确定这些化合物是否能与D-1受体结合。发现氯丙嗪以及氯丙嗪的二甲锍和三甲铵类似物能抑制[3H]SCH 22390的结合,这三种化合物对其抑制作用达到最大程度且相同。此外,这些化合物的抑制曲线符合单点结合模型,表明它们与单一类别的位点结合。然而,虽然永久带电的氯丙嗪类似物能够抑制[3H]SCH-23390的结合,但它们的效力比氯丙嗪低得多。DA和二甲基DA也能够抑制[3H]SCH 23390的结合。然而,DA的永久带电的二甲锍和三甲铵类似物在抑制[3H]SCH 23390结合方面无效。此外,永久不带电的甲硫醚类似物也不抑制结合。这些研究表明,氯丙嗪的永久带电类似物能够与纹状体D-1受体结合,这与D-1受体上一个以阳离子形式与拮抗剂相互作用的阴离子识别位点一致。此外,似乎与D-1受体结合不需要氮原子,因为氯丙嗪的锍类似物与受体的结合程度与氯丙嗪相同。然而,由于DA的永久带电或不带电类似物都不与D-1受体结合,多巴胺能激动剂的带电形式是否能结合仍不清楚。与母体胺(氯丙嗪、DA、二甲基DA)相比,永久带电类似物在与D-1受体结合方面效力较低或无效,这可能反映出永久带电类似物无法与受体的阴离子位点进行氢键结合。